Zhao Chunhua

[Expert Profile] Zhao Chunhua, Chief Physician, Professor, Doctoral Supervisor, is an authoritative expert in myeloproliferative neoplasms in China, working in the Department of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. He has long been dedicated to the clinical diagnosis, treatment, and scientific research of polycythemia vera, myeloproliferative neoplasms, and other hematological diseases, and is an important expert in hematology in China.

[Education & Career] Professor Zhao Chunhua graduated from Shanghai Second Medical University (now Shanghai Jiao Tong University School of Medicine), completed systematic clinical training at Ruijin Hospital, and further studied at famous international hematology centers. He has long been engaged in clinical and research work in hematology, holding academic positions in relevant groups of the Hematology Branch of the Chinese Medical Association. He has presided over grants from the National Natural Science Foundation of China and major Shanghai municipal research programs, and has accumulated extensive diagnosis and treatment experience in the field of myeloproliferative neoplasms.

[Areas of Expertise] Professor Zhao specializes in the diagnosis and treatment of myeloproliferative neoplasms (MPN) such as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis, as well as comprehensive management of various difficult hematological diseases. He has extensive experience in driver gene testing interpretation (such as JAK2), thrombotic risk assessment, phlebotomy, and standardized application of cytoreductive drugs (hydroxyurea, JAK inhibitors, etc.). He excels at developing individualized plans for MPN patients with "abnormally elevated red blood cells and platelets," helping patients control blood counts and prevent thrombotic and hemorrhagic complications.

[Academic Achievements & Industry Contributions] Professor Zhao has led a series of clinical studies on myeloproliferative neoplasms, systematically evaluating the molecular characteristics, prognostic factors, and treatment strategies of MPN in Chinese populations, with findings published in authoritative domestic and international journals. He has participated in the development of Chinese MPN diagnosis and treatment guidelines and expert consensus statements, actively promoted the standardized application of driver gene testing and targeted therapy in MPN, and organized multi-center clinical research and whole-course patient management exploration, making important contributions to improving the standardized diagnosis and treatment level of myeloproliferative neoplasms in China.

[Clinical Practice & Outstanding Contributions] Professor Zhao has long held expert hematology clinics, cumulatively treating tens of thousands of patients with myeloproliferative neoplasms and various hematological conditions, providing clear diagnoses and thrombotic risk prevention for numerous patients with "abnormal blood counts." He is rigorous and responsible with patients, insisting on standardized follow-up and whole-course management, and is deeply trusted by patients. He has repeatedly organized hematology science popularization and free clinics, actively participated in grassroots hematology diagnosis and treatment support, and is a reliable hematology expert in the hearts of patients.

[Honors & Reputation] Professor Zhao Chunhua serves as Director of the Department of Hematology at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, among other academic positions. He has presided over national-level projects including key grants from the National Natural Science Foundation of China, and is a senior expert in the field of hematology in China. He has profound expertise in standardized diagnosis, treatment, and whole-course management of polycythemia vera and myeloproliferative neoplasms. He has led research on molecular diagnosis and targeted therapy of myeloproliferative neoplasms, promoted standardized application of novel drugs such as JAK inhibitors, and participated in the development of multiple hematology diagnosis and treatment guidelines. For decades on the clinical front lines, he has helped numerous hematology patients receive clear diagnoses, standardized treatment, and reduced complications, and is deeply trusted by patients and respected by peers alike.